Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to α‐interferon treatment in patients with chronic hepatitis C
A. Airoldi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Giovambattista Pinzello(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Claudio Zavaglia(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Marcello Vangeli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), M. Martinetti(Policlinico San Matteo Fondazione), M. Asti(Policlinico San Matteo Fondazione), Angelo Rossini(Centro Universitário Barão de Mauá), Enrico Maria Silini(Ospedale di Parma), L. Salvaneschi(Policlinico San Matteo Fondazione), Carmine Tinelli(Policlinico San Matteo Fondazione)
Cited by 15
Related Papers
Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer
|European Journal of Cancer|2015|386
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133
Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study
|The American Journal of Gastroenterology|2002|80